Joulferon: Withdrawal of the marketing authorisation application

albinterferon alfa-2b

Overview

On 16 April 2010, Novartis Europharm Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Joulferon, for the treatment of hepatitis C infection.

  • List item

    Questions and answers on withdrawal of marketing authorisation application for Joulferon (PDF/102.2 KB)


    First published: 29/04/2010
    Last updated: 29/04/2010

  • Key facts

    Name
    Joulferon
    Product number
    EMEA/H/C/002166
    International non-proprietary name (INN) or common name
    • albinterferon alfa-2b
    Active substance
    • albinterferon alfa-2b
    Date of withdrawal
    16/04/2010
    Company making the application
    Novartis Europharm Limited
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating